GlassScriptPhysician profile
Robert J Duncan
NPI 1669492609
$4,961.48
in general payments reported to CMS, 2019-2025
40 companies · $1,533 in 2025
The $1,533 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.33 · 2022: $518 · 2023: $1,294 · 2024: $1,572 · 2025: $1,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,398.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $705.63 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $612.34 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $419.12 | 2023-2025 | Calquence, Lynparza, Enhertu |
| Abbvie INC. | $400.12 | 2024-2025 | |
| Janssen Biotech, INC. | $373.02 | 2022-2025 | Darzalex, Talvey, Imbruvica |
| Merck Sharp & Dohme LLC | $283.39 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $210.22 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $182.55 | 2022-2025 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $172.14 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Eisai INC. | $140.24 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $137.23 | 2023-2025 | Ultomiris |
| Agios Pharmaceuticals, INC. | $123.26 | 2022-2024 | Pyrukynd |
| Regeneron Healthcare Solutions, INC. | $111.52 | 2023-2025 | Libtayo |
| Rigel Pharmaceuticals, INC. | $107.78 | 2023-2024 | Tavalisse, Rezlidhia |
| Astellas Pharma US INC | $107.62 | 2022-2025 | Vyloy, Padcev |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $84.71 | 2023 | Epkinly, Imbruvica |
| Revance Therapeutics, INC. | $83.18 | 2024 | Daxxify |
| Bayer Healthcare Pharmaceuticals INC. | $60.22 | 2023-2025 | |
| Seagen INC. | $56.01 | 2022-2023 | Adcetris |
| Global Blood Therapeutics, INC. | $50.30 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.85 | 2024-2025 | Fruzaqla, Iclusig |
| Progenics Pharmaceuticals, INC. | $42.20 | 2024 | |
| Karyopharm Therapeutics INC. | $39.75 | 2023-2025 | Xpovio |
| Genzyme Corporation | $39.69 | 2023-2024 | |
| Tempus Ai, INC | $38.71 | 2025 | Xt Cdx |
| Emmaus Medical, INC. | $37.51 | 2023-2025 | Endari |
| Beone Medicines USA, INC. | $37.08 | 2025 | Brukinsa |
| Celgene Corporation | $34.11 | 2022-2025 | Reblozyl |
| G1 Therapeutics, INC. | $29.12 | 2022 | |
| Genmab U.S., INC. | $27.86 | 2023 | Tivdak |
| Exelixis INC. | $24.01 | 2024 | Cabometyx |
| Sobi, INC | $21.38 | 2023 | |
| Pharmacosmos Therapeutics INC. | $20.01 | 2024 | Monoferric |
| Pharmaessentia USA Corporation | $18.63 | 2025 | Besremi |
| Taiho Oncology, INC. | $15.40 | 2023 | |
| Secura Bio, INC. | $15.22 | 2024 | Copiktra |
| Dova Pharmaceuticals | $15.03 | 2021 | |
| Genentech USA, INC. | $14.01 | 2024 | Tecentriq, Phesgo, Polivy |
| Incyte Corporation | $13.58 | 2025 | Zynyz |
| Mirati Therapeutics, INC. | $12.73 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.